Abstract
On August 30, 2017, the U.S. Food and Drug Administration (FDA) approved Novartis' tisagenlecleucel (CTL-019, Kymriah), which is a synthetic bioimmune......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
